Stock code: 000963 Stock abbreviation: Huadong Medicine Announcement No.: 2021-076
Huadong Medicine Co., Ltd.
The Third Quarterly Report 2021
The Company and all members of the Board of Directors hereby guarantee that the information
presented in this report is authentic, accurate and complete and free of any false records,
misleading statements or material omissions.
Important Declaration:
1.The Board of Directors, Board of Supervisors, directors, supervisors and senior management of
Huadong Medicine Co., Ltd. (hereinafter referred to as the “Company”) hereby guarantee that the
information presented in this report is authentic, accurate and complete and free of any false records,
misleading statements or material omissions, and shall undertake indiv idual and joint legal
liabilities.
2.The Company’s legal representative and the officer in charge of accounting, and head of
accounting department (accounti ng supervisor) hereby declare and guarantee that the financial
statements in this quarter report are authentic, accurate and complete.
3.Has the third quarterly report been audited?
□Yes √ No
This report is prepared both in Chi nese and English. Should there be any discrepancy between the
Chinese and English versions, the Chinese versionshall prevail.
I. Key financialdata
(I) Key Accounting Data and Financial Indicators
Whether the Company needs to perform retroactive adjustment or restatement of previous accounting data
□Yes √ No
Change from the
The current reporting Change of the current From the beginning of the beginning of the year to
period reporting period over the year to the end of the the end of the reporting
same period last year reporting period period over the
same period last year
Operating revenue (yuan) 8,748,039,460.66 -1.04% 25,927,477,363.27 1.67%
Net profit attributable to
shareholders of listed 595,038,254.49 -9.88% 1,895,384,579.34 -20.74%
companies (yuan)
Net profit attributable to 568,039,187.19 -9.00% 1,762,020,074.37 -13.24%
shareholders of listed
companies after
deducting non-recurring
gains/losses (yuan)
Net cash flow from
operating activities —— —— 2,105,916,826.72 10.73%
(yuan)
Basic earnings per share 0.3401 -9.88% 1.0832 -20.74%
(yuan/share)
Diluted earnings per 0.3401 -9.88% 1.0832 -20.74%
share (yuan/share)
Weighted average return 3.75% -1.00% 12.28% -5.41%
on equity (ROE)
End of the current End of last year Change of the end of the current reporting period
reporting period over the end of last year
Totalassets (yuan) 27,687,711,922.81 24,201,348,154.75 14.41%
Owners’ equity
attributable to 16,250,585,502.88 14,619,821,308.60 11.15%
shareholders of
listed companies (yuan)
Share capitalof the Company as of the trading day before disclosure :
Share capitalof the Company as of the trading day before 1,749,809,548
disclosure (share)
Fully diluted earnings per share calculated on the basis of the latest Share capita l
Dividends pa id on preferred shares 0.00
Perpetualbond interest paid (yuan) 0.00
Fully diluted earnings per share calculated on the basis of the 1.0832
latest Share capital(yuan/s hare)
(II)Items andamounts of non-recurring gains/losses
√Applicable □ N/A
Amount (from the
Item Amount of the current beginning of the year to Note
reporting period the end of the reporting
period)
Gains/losses on disposa lof non-current assets
(including the written-off part of the accrued assets -356,832.47 -466,951.55
impairment reserve)
Government grants included in current
gains/losses(excluding those close ly re lated to nor ma l 19,665,596.43 157,973,691.62
operating activities, in line w
查看PDF原文
